exRNAdisease

Entry Detail

---



General Information

Database ID: exR0088980 RNA Name: hsa-miR-512-3p RNA Type: miRNA Chromosome: chr19 Starnd: + Coordinate: Start Site(bp): 53666729 End Site(bp): 53666750 External Links: hsa-miR-512-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand IFNAR1 chr21 33324429 33359864 + RAI14 chr5 34656328 34832612 + NAA16 chr13 41311267 41377030 + TOB2 chr22 41433494 41446801 - ASB1 chr2 238426742 238452250 + RIT1 chr1 155897808 155911404 - C9orf40 chr9 74946583 74952912 - STK40 chr1 36339624 36385896 - LETMD1 chr12 51047962 51060424 + IQSEC1 chr3 12897043 13283281 - COQ10B chr2 197453423 197475308 + ZCCHC3 chr20 297570 300321 + FAM120AOS chr9 93431441 93453581 - NSD2 chr4 1871393 1982207 + MTMR12 chr5 32226994 32312987 - ZNF28 chr19 52797408 52857600 - WASL chr7 123681943 123749003 - TOMM6 chr6 41787662 41789898 + AP3M1 chr10 74120255 74151063 - OCRL chrX 129539849 129592561 + SYVN1 chr11 65121780 65134533 - LONP2 chr16 48244300 48363122 + MID1IP1 chrX 38801432 38806537 + SBF1 chr22 50445000 50475035 - TNRC6A chr16 24610209 24827632 + RAB31 chr18 9708275 9862551 + UHRF1BP1 chr6 34792015 34883138 + ERMP1 chr9 5765076 5833117 - ATP6V1E1 chr22 17592136 17628749 - TRIB1 chr8 125430358 125438403 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001731 chr7 100731990 100738448 + hsa_circ_0000384 chr12 27867712 27877119 + hsa_circ_0001159 chr20 40161688 40179999 - hsa_circ_0001865 chr9 86292641 86293514 - lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC004687.1 chr17 58330884 58332508 - AC091564.7 chr11 6610883 6616594 - AC092718.4 chr16 81030770 81031485 + FGD5-AS1 chr3 14920347 14948424 - MIR497HG chr17 7015818 7019659 - NEAT1 chr11 65422774 65445540 + NORAD chr20 36045618 36051018 - TUG1 chr22 30969245 30979395 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.